down arrow

Baxter International, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0718131099
USD
18.48
-0.41 (-2.17%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

18.3318.93

52 Week

17.4037.74
Valuation
Technical
Day's Volume

CASH

7.93 M

Shareholding (Mar 2025)

FII

16.25%

Held by 363 FIIs

DII

31.28%

Held by 111 DIIs

Promoter

0.93%

How big is Baxter International, Inc.?

22-Jun-2025

As of Jun 18, Baxter International, Inc. has a market capitalization of $20.62 billion, with net sales of $11.89 billion and a net profit of -$674 million over the last four quarters.

Market Cap: As of Jun 18, Baxter International, Inc. has a market capitalization of 20,615.97 million, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Baxter International, Inc. reported net sales of 11,889.00 million and a net profit of -674.00 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 6,964.00 million and total assets of 25,782.00 million.

Read More

What does Baxter International, Inc. do?

22-Jun-2025

Baxter International, Inc. specializes in renal and hospital products within the Pharmaceuticals & Biotechnology industry, with a recent net sales of $2.625 billion and a market cap of approximately $20.62 billion. Key financial metrics include a P/E ratio of 31.00 and a dividend yield of 1.97%.

Overview:<BR>Baxter International, Inc. provides renal and hospital products within the Pharmaceuticals & Biotechnology industry and operates in the large-cap market segment.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2,625 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 64 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 20,615.97 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 31.00 <BR>Dividend Yield: 1.97% <BR>Debt Equity: 1.10 <BR>Return on Equity: 9.41% <BR>Price to Book: 2.91 <BR><BR>Contact Details:<BR>Address: 1 Baxter Pkwy, DEERFIELD IL: 60015-4625 <BR>Tel: 1 847 9482000 <BR>Website: https://www.baxter.com/

Read More

Who are in the management team of Baxter International, Inc.?

22-Jun-2025

As of March 2022, Baxter International, Inc.'s management team includes Mr. Jose Almeida as Chairman, President, and CEO, and Mr. Thomas Stallkamp as Lead Independent Director, along with several Independent Directors.

As of March 2022, the management team of Baxter International, Inc. includes Mr. Jose Almeida, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features Mr. Thomas Stallkamp as the Lead Independent Director, along with several Independent Directors: Mr. Thomas Chen, Mr. John Forsyth, Dr. James Gavin, and Mr. Peter Hellman.

Read More

Is Baxter International, Inc. overvalued or undervalued?

20-Sep-2025

As of February 8, 2024, Baxter International, Inc. is considered overvalued with a P/E ratio of 31 compared to its peer Align Technology's 20.46, and has underperformed the S&P 500 with a year-to-date return of -18.76% and a three-year decline of 59.28%.

As of 8 February 2024, Baxter International, Inc. has moved from a fair to a risky valuation grade. The company appears to be overvalued, as indicated by its P/E ratio of 31, which is significantly higher than its peer Align Technology, Inc. with a P/E of 20.46. Additionally, Baxter's EV to EBITDA ratio stands at 32.83, compared to Align's 11.41, further highlighting the disparity in valuation metrics. The Price to Book Value of 2.94 also suggests that the stock is trading at a premium relative to its book value.<BR><BR>In terms of recent performance, Baxter has underperformed against the S&P 500, with a year-to-date return of -18.76% compared to the index's 12.22%. Over the past three years, Baxter's stock has declined by 59.28%, while the S&P 500 has gained 70.41%, reinforcing the notion that the stock is currently overvalued.

Read More

Is Baxter International, Inc. technically bullish or bearish?

20-Sep-2025

As of July 14, 2025, Baxter International, Inc. is in a bearish trend, indicated by negative signals from MACD and moving averages, despite a bullish weekly RSI, and has significantly underperformed the S&P 500 with year-to-date and one-year returns of -18.76% and -39.83%, respectively.

As of 14 July 2025, the technical trend for Baxter International, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with a strong indication from the weekly and monthly MACD, both showing bearish signals. The daily moving averages also confirm a bearish trend. Although the weekly RSI is bullish, it is overshadowed by the overall bearish indicators from Bollinger Bands and KST. The Dow Theory indicates a mildly bearish stance on the weekly timeframe. <BR><BR>In terms of performance, Baxter has underperformed significantly compared to the S&P 500 across all multi-period returns, with a year-to-date return of -18.76% versus the S&P 500's 12.22%, and a one-year return of -39.83% compared to the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Weak Long Term Fundamental Strength with a -17.50% CAGR growth in Operating Profits over the last 5 years

  • Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.86 times
2

The company has declared Negative results for the last 3 consecutive quarters

3

Risky -

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 16,610 Million (Small Cap)

stock-summary
P/E

31.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.08%

stock-summary
Debt Equity

1.07

stock-summary
Return on Equity

7.91%

stock-summary
Price to Book

2.27

Revenue and Profits:
Net Sales:
2,810 Million
(Quarterly Results - Jun 2025)
Net Profit:
122 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-21.63%
0%
-21.63%
6 Months
-38.34%
0%
-38.34%
1 Year
-44.03%
0%
-44.03%
2 Years
-49.91%
0%
-49.91%
3 Years
-65.28%
0%
-65.28%
4 Years
-76.32%
0%
-76.32%
5 Years
-76.31%
0%
-76.31%

Baxter International, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Baxter International Stock Hits Day Low of $18.44 Amid Price Pressure

Baxter International Stock Hits Day Low of $18.44 Amid Price Pressure

Baxter International, Inc. faced notable volatility on October 30, 2025, with a significant stock decline. The company has struggled recently, with substantial drops in performance over various timeframes. Financial challenges include a high Debt to EBITDA ratio and a marked decrease in net sales, contributing to ongoing negative results.

Read More
Baxter International Opens with 15.25% Gap Down Amid Market Concerns

Baxter International Opens with 15.25% Gap Down Amid Market Concerns

Baxter International, Inc. experienced a notable decline in its stock performance, contrasting with the stable S&P 500. The company has faced a significant drop over the past month, with a market capitalization of approximately USD 16.61 billion and a premium P/E ratio, alongside a moderate debt-to-equity ratio.

Read More
Baxter International Hits 52-Week Low at $18.44 Amidst Declining Sales

Baxter International Hits 52-Week Low at $18.44 Amidst Declining Sales

Baxter International, Inc. has reached a new 52-week low, reflecting a difficult year marked by a significant stock price decline. The company has reported negative results for three consecutive quarters, with declining net sales and profitability, alongside a high debt-to-EBITDA ratio, indicating ongoing financial challenges.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-0.93%
EBIT Growth (5y)
-17.50%
EBIT to Interest (avg)
5.83
Debt to EBITDA (avg)
3.86
Net Debt to Equity (avg)
1.10
Sales to Capital Employed (avg)
0.67
Tax Ratio
5.34%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
9.07%
ROE (avg)
13.65%
Valuation key factors
Factor
Value
P/E Ratio
31
Industry P/E
Price to Book Value
2.94
EV to EBIT
32.83
EV to EBITDA
16.08
EV to Capital Employed
1.93
EV to Sales
2.41
PEG Ratio
NA
Dividend Yield
1.95%
ROCE (Latest)
5.87%
ROE (Latest)
9.41%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Bearish
Bearish
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 144 Schemes (51.42%)

Foreign Institutions

Held by 363 Foreign Institutions (16.25%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -26.29% vs 2.83% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 139.23% vs -61.14% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,810.00",
          "val2": "3,812.00",
          "chgp": "-26.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "452.00",
          "val2": "634.00",
          "chgp": "-28.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "70.00",
          "val2": "102.00",
          "chgp": "-31.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-23.00",
          "val2": "-541.00",
          "chgp": "95.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "122.00",
          "val2": "-311.00",
          "chgp": "139.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "69.40%",
          "val2": "90.80%",
          "chgp": "-2.14%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 2.66% vs -28.58% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -280.11% vs 106.82% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "10,636.00",
          "val2": "10,360.00",
          "chgp": "2.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,684.00",
          "val2": "1,887.00",
          "chgp": "-10.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "402.00",
          "val2": "502.00",
          "chgp": "-19.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-711.00",
          "val2": "-195.00",
          "chgp": "-264.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-326.00",
          "val2": "181.00",
          "chgp": "-280.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "64.60%",
          "val2": "87.20%",
          "chgp": "-2.26%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
2,810.00
3,812.00
-26.29%
Operating Profit (PBDIT) excl Other Income
452.00
634.00
-28.71%
Interest
70.00
102.00
-31.37%
Exceptional Items
-23.00
-541.00
95.75%
Consolidate Net Profit
122.00
-311.00
139.23%
Operating Profit Margin (Excl OI)
69.40%
90.80%
-2.14%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -26.29% vs 2.83% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 139.23% vs -61.14% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
10,636.00
10,360.00
2.66%
Operating Profit (PBDIT) excl Other Income
1,684.00
1,887.00
-10.76%
Interest
402.00
502.00
-19.92%
Exceptional Items
-711.00
-195.00
-264.62%
Consolidate Net Profit
-326.00
181.00
-280.11%
Operating Profit Margin (Excl OI)
64.60%
87.20%
-2.26%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 2.66% vs -28.58% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -280.11% vs 106.82% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Baxter International, Inc. stock-summary
stock-summary
Baxter International, Inc.
Pharmaceuticals & Biotechnology
Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.
Company Coordinates stock-summary
Company Details
1 Baxter Pkwy , DEERFIELD IL : 60015-4625
stock-summary
Tel: 1 847 9482000
stock-summary
https://www.baxter.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."